| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Iloprost (Ciloprost; ZK-36374; Trade names: Ventavis, Ilomedine), a novel potent synthetic analog of prostacyclin PGI2, is an approved drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues. This results in elevated blood pressure and tissue damage. In order to restore blood flow, iloprost dilates, or opens, blood vessels.
| Targets |
IP
|
|---|---|
| ln Vitro |
Prostacyclin (PGI2) is produced in the fluid of the oviduct and promotes the development of the embryo[1].
Iloprost, a PGI2 analog, influences the developmental competence and maturation of bovine oocytes[1]. Iloprost (0.5 μM; 22–24 h) raises the percentage of expanded blastocysts and blastocyst rates in bovine embryos[1]. Iloprost (0.5 μM; 22-24 h) assists maturation rates and cumulus cell expansion of bovine oocytes, and increases the mRNA expression of genes related to cumulus expansion[1]. Iloprost (0.5 μM; 22–24 h) stimulates an anti-apoptotic balance in the transcription of apoptosis-related genes (BCL2 and BAX), thereby decreasing the incidence of apoptosis in COCs [1]. |
| ln Vivo |
Iloprost (0.3 mg/kg/min; via s.c. mini pumps; 33 d) possesses a strong anti-metastatic effect in a rat tumor model that spontaneously metastasizes[2].
Iloprost (0.2 mg/kg/d; i.p.; 10 d) reduces inflammation and the effects of hyperoxia in the lungs of newborn mice; the impairment caused by hyperoxia is mediated by Cyclooxygenase-2 (COX-2/PTGS2)[3]. Iloprost (0.2 mg/kg; i.v. or i.p.) has a brief half-life and is often used in treatment as a frequent (every 2-4 hours) inhalation[4]. |
| Cell Assay |
Cell Line: Bovine oocytes: cumulus oocyte complexes (COCs)
Concentration: 0.5 μM Incubation Time: 22-24 hours Result: Increased mRNA expression levels of cysteine proteinases cathepsins, including ADAM17, AREG, and TNFAIP6 23 and cathepsin genes (CTSK and CTSS). |
| Animal Protocol |
Spontaneously metastasizing R 3327 MAT Lu prostate carcinoma in Cop rat
0.3 mg/kg/min Subcutaneous administration via Alzet mini pumps; continuously for 33 days |
| References |
| Molecular Formula |
C22H32O4
|
|---|---|
| Molecular Weight |
360.4871
|
| Exact Mass |
360.23
|
| Elemental Analysis |
C, 73.30; H, 8.95; O, 17.75
|
| CAS # |
78919-13-8
|
| Related CAS # |
Iloprost-d4; 1035094-10-0
|
| Appearance |
Clear solution in acetone (white Oily or waxy solid in pure form)
|
| SMILES |
CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)O
|
| InChi Key |
HIFJCPQKFCZDDL-ACWOEMLNSA-N
|
| InChi Code |
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
|
| Chemical Name |
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
|
| Synonyms |
ZK-36374; Endoprost; ZK36374; Iloprost; ZK00036374; ZK 36374; Ilomedin; BAYQ6256; ZK-00036374; BAY-Q6256; Ciloprost; Ventavis; CHEMBL494
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~277.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.94 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7740 mL | 13.8700 mL | 27.7400 mL | |
| 5 mM | 0.5548 mL | 2.7740 mL | 5.5480 mL | |
| 10 mM | 0.2774 mL | 1.3870 mL | 2.7740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05411107 | Not yet recruiting | Drug: Iloprost Procedure: Bronchoscopy |
Lung Carcinoma Bronchial Epithelial Dysplasia |
National Cancer Institute (NCI) |
April 1, 2024 | Phase 2 |
| NCT04543682 | Recruiting | Drug: 0.125 ng/kg/min Iloprost Drug: 0.25 ng/kg/min Iloprost |
Proximal Humeral Fracture | Charite University, Berlin, Germany |
May 12, 2022 | Phase 1 Phase 2 |
| NCT04445246 | Completed | Drug: Inhaled ILOPROST | COVID-19 ARDS, Human |
Hamad Medical Corporation | May 23, 2020 | Phase 2 |
| NCT01209533 | Completed | Drug: Iloprost | Asthma | Vanderbilt University | September 2010 | Early Phase 1 |
| NCT04123444 | Completed | Drug: Iloprost Drug: Isotonic saline |
Septic Shock | Jakob Stensballe, MD, PhD | October 30, 2019 | Phase 2 Phase 3 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
